Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01311674 · ClinicalTrials.gov registry record · Phase 3
Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
A Phase 3 study, sponsored by Emergent BioSolutions.
- Terminated
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT01311674 is a Phase 3 study that was terminated before completion, run by Emergent BioSolutions. The registered enrollment target is 141 participants.
The verdict
NCT01311674, a Phase 3 study, was terminated before completion, sponsored by Emergent BioSolutions.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
Hepatitis B Virus Antibody Booster Program
Interventions
- BIOLOGICAL hepatitis B vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01311674
The ClinicalTrials.gov registry entry for NCT01311674 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hepatitis B vaccine is the first listed.
NCT01311674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01311674 about?
NCT01311674 is a clinical study titled "Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)". Hepatitis B Virus Antibody Booster Program
What is the current status of trial NCT01311674?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2009-09. Estimated completion is 2011-03-11.
What interventions are being tested in trial NCT01311674?
The interventions under investigation include: hepatitis B vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01311674?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.